中国保健营养（中旬刊）
中國保健營養（中旬刊）
중국보건영양（중순간）
China Hwalth Care & nutrition
2013年
8期
884-884
,共1页
建平%李卫峰%姚净%龚晴勇
建平%李衛峰%姚淨%龔晴勇
건평%리위봉%요정%공청용
西酞普兰%弥可保%奥沙利铂%周围神经病变
西酞普蘭%瀰可保%奧沙利鉑%週圍神經病變
서태보란%미가보%오사리박%주위신경병변
citalopram%mecobalamin%oxaliplatin%peripheral neuropathy
目的：探讨西酞普兰联合弥可保治疗恶性胶质瘤奥沙利铂化疗后引起周围神经病变的临床疗效和安全性。方法：选取2009-2012年来我院恶性胶质瘤奥沙利铂化疗后引起周围神经病变的患者68例，通过计算机随机分组的方式将其随机分为实验组和对照组，每组均为34例，两组患者均给予相同的基础对症治疗，在此基础上实验组给予西酞普兰联合弥可保治疗，对照组患者给予维生素 B12治疗，观察两组患者的总体治疗有效情况及神经传导速度、不良情况发生情况。结果：实验组患者的总体治疗有效率显著高于对照组（P<0.05），实验组患者的神经传导速度也要显著快于对照组（P<0.05），两组均无显著不良反应发生。结论：西酞普兰联合弥可保治疗恶性胶质瘤奥沙利铂化疗后引起周围神经病变临床疗效显著，安全性高。
目的：探討西酞普蘭聯閤瀰可保治療噁性膠質瘤奧沙利鉑化療後引起週圍神經病變的臨床療效和安全性。方法：選取2009-2012年來我院噁性膠質瘤奧沙利鉑化療後引起週圍神經病變的患者68例，通過計算機隨機分組的方式將其隨機分為實驗組和對照組，每組均為34例，兩組患者均給予相同的基礎對癥治療，在此基礎上實驗組給予西酞普蘭聯閤瀰可保治療，對照組患者給予維生素 B12治療，觀察兩組患者的總體治療有效情況及神經傳導速度、不良情況髮生情況。結果：實驗組患者的總體治療有效率顯著高于對照組（P<0.05），實驗組患者的神經傳導速度也要顯著快于對照組（P<0.05），兩組均無顯著不良反應髮生。結論：西酞普蘭聯閤瀰可保治療噁性膠質瘤奧沙利鉑化療後引起週圍神經病變臨床療效顯著，安全性高。
목적：탐토서태보란연합미가보치료악성효질류오사리박화료후인기주위신경병변적림상료효화안전성。방법：선취2009-2012년래아원악성효질류오사리박화료후인기주위신경병변적환자68례，통과계산궤수궤분조적방식장기수궤분위실험조화대조조，매조균위34례，량조환자균급여상동적기출대증치료，재차기출상실험조급여서태보란연합미가보치료，대조조환자급여유생소 B12치료，관찰량조환자적총체치료유효정황급신경전도속도、불량정황발생정황。결과：실험조환자적총체치료유효솔현저고우대조조（P<0.05），실험조환자적신경전도속도야요현저쾌우대조조（P<0.05），량조균무현저불량반응발생。결론：서태보란연합미가보치료악성효질류오사리박화료후인기주위신경병변림상료효현저，안전성고。
Objectives:Obeserve the clinical efficacy and safety of citalopram and mecobalamin in the treatment of the peripheral neuropathy which is caused after the oxaliplatin chemotherapy in malignant glioma. Methods: Choose 68 cases of the peripheral neuropathy disease patients who are caused after the oxaliplatin chemotherapy in malignant glioma at our hospital form 2009 to 2012, random grouping by computer, it can be divided into the experimental group and control group, each group was 34 cases,both of two groups of patients were given the same basic symptomatic treatment,meanwhile the experimental group were treated by citalopram and mecobalamin, and control group were treated with vitamin B12 therapy, observed the overal effective treatment and nerve conduction velocity,the occurrence of adverse events of two groups of patients. Results: the overal treatment efficiency of the experimental group of patients was significantly higher than the control group (P < 0.05), the nerve conduction velocity of the experimental group of patients was also significantly faster than the control group (P <0.05), both of two groups had no significant adverse reactions. Conclusions: The clinical efficacy of citalopram and mecobalamin in the treatment of the peripheral neuropathy which is caused after the oxaliplatin chemotherapy in malignant glioma is distinct,the safety is high.
